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Abstract. Analog-sensitive (AS) kinases contain large to small mutations in the gatekeeper 
position rendering them susceptible to inhibition with bulky analogs of pyrazolopyrimidine-
based Src kinase inhibitors (e.g. PP1). This ‘bump-hole’ method has been utilized for at least 
85 of ~520 kinases, but many kinases are intolerant to this approach. To expand the scope of 
AS-kinase technology, we designed type II kinase inhibitors, ASDO2/6 (Analog-Sensitive 
‘DFG-Out’ kinase inhibitors-2/6), that target the ‘DFG-out’ conformation of cysteine (Cys)-
gatekeeper kinases with submicromolar potency. We validated this system in vitro against 
Greatwall kinase (GWL), Aurora-A kinase and Cyclin-dependent kinase-1 and in cells using 
M110C-GWL expressing mouse embryonic fibroblasts. These Cys-gatekeeper kinases were 
sensitive to ASDO2/6-inhibition, but not AS-kinase inhibitor 3MB-PP1 and vice versa. These 
compounds, with AS-kinase inhibitors, have the potential to inhibit multiple AS-kinases 
independently with applications in systems level and translational kinase research as well as 
the rational design of type II kinase inhibitors targeting endogenous kinases. 
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Overview of kinases and analog-sensitive kinase technology. Eukaryotic protein kinases 
represent one of the largest protein families in the human genome with ~520 members and 
constituting about 2% of all human genes1. These enzymes catalyze the transfer of the g-
phosphate group from ATP to serine (Ser), threonine (Thr) or tyrosine residues on their 
substrate proteins or peptides. This post-translational modification is a critical and nearly 
ubiquitous mode of intracellular signaling, with about 30% of all proteins being 
phosphorylated2, 3. It is, therefore, to no surprise that aberrant expression and activation of this 
class of proteins often leads to a variety of diseases with about 244 kinases mapping to 
disease loci and cancer amplicons1, 4, 5. 
 
Figure 1. AS- and ASDO-kinase systems.  A) Tertiary structure of the Staurosporine-bound 
GWL domain with key features highlighted (PDB: 5LOH). B) Chemical structures of 1NM-PP1 
and ASDO2. C) Cartoon depicting a wild type kinase (top) with a bulky methionine gatekeeper 
residue. Mutating the gatekeeper residue to a smaller alanine (or glycine) residue generates 
an analog-sensitive (AS) kinase (middle). Mutating the gatekeeper residue to a cysteine 
generates an AS-kinase that is susceptible to inhibition by novel ‘DFG-out’ conformation-
targeting inhibitors (ASDOs; ASDO2 depicted here, bottom). The AS- and ASDO-kinase 
  
3 
systems are orthogonal to wild type kinases and each other. D) A panel of reversible type I 
inhibitors that target alanine- or glycine-gatekeeper mutants. E) A panel of irreversible type I 
inhibitors that target cysteine mutations in the gatekeeper, hinge or G-loop regions. Structural 
features highlighted in BLUE complement the expanded hydrophobic pocket that is generated 
by mutation of the gatekeeper residue to alanine or glycine and features highlighted in RED 
represent cysteine-reactive, electrophilic warheads (fluoromethylketone, acrylamide and 
vinylsulfone). 
 
One way to study kinase function and manage dysregulated kinases is through development 
of selective kinase inhibitors; however, due to the high degree of structural similarity, 
particularly in and around the ATP-binding pocket, it is often difficult to target an individual 
kinase with small-molecule inhibitors. One way to circumvent this issue is by employing a 
chemical-genetic strategy that takes advantage of a structurally conserved, mostly 
hydrophobic residue within the kinase active-site, termed the gatekeeper residue6-8. Mutation 
of this residue from a normally bulky residue to a smaller one, such as alanine (Ala) or glycine 
(Gly), engenders an analog-sensitive (AS) kinase containing a unique binding-site that can be 
exploited pharmacologically with bulky ATP-analogs such as 1NM-PP18, 3MB-PP18 and the 
recently developed staralogs7 (Figure 1A-D). This ‘bump-hole’ method has been utilized for 
the study of at least 85 different kinases, yet despite this level of success there are still a 
number of kinases, coined ‘intolerant’ kinases, that do not tolerate gatekeeper mutations8-11. 
To expand the scope of AS-technology, researchers have identified second-site mutations, or 
suppressor of Gly gatekeeper mutations (sogg), that restore the kinase activity to some 
‘intolerant’ AS-kinases (applied to at least 11 kinases so far) when the gatekeeper is Gly or 
Ala8, 10. In addition, electrophile-sensitive (ES)-kinases can be selectively inhibited by 
electrophilic, bulky PP1- or ATP-analogs (Figure 1E) (e.g. fluoromethylketobenzyl (FMKB)-
PP1, acrylamido-anilinoquinazolines (AQZ) and 5’-vinylsulfonyl adenosine (VSA)) by targeting 
cysteine (Cys)-mutations within the gatekeeper or other positions vicinal to the ATP-binding 
pocket (i.e. in the Gly-rich loop (G-loop) or hinge region, Figure 1A)9, 12-18 . However, these 
approaches appear to be highly specific to individual kinases and not widely applicable. This 
also limits the possibility to differentially inhibit two kinases with two orthogonal chemical 
genetic systems. Such a dual bio-orthogonal approach would be ideal for investigating kinase 
signaling crosstalk, synthetic lethality and many other areas of systems biology and 
translational research across a diverse set of kinase drug targets.  
 
In this study, we report the development of a new chemical-genetic approach based on a Cys-
gatekeeper mutation and non-covalent, type II mode of kinase inhibition that targets the 
inactive “DFG-out” kinase conformation (Figure 1)19. We verified this approach with three 
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divergent Ser/Thr-kinases: Greatwall kinase (GWL), Aurora-A kinase (AAK) and Cyclin-
dependent kinase-1 (Cdk1). To demonstrate compound efficacy in cells, we measured 
substrate phosphorylation and cellular proliferation, a phenotype functionally linked to GWL 
activity20, 21, in wild type (WT)- and M110C (MC)-GWL expressing mouse embryonic 
fibroblasts (MEFs). ASDO2 (Analog-Sensitive “DFG-Out” kinase inhibitor-2) specifically 
inhibited phosphorylation of the physiologic GWL substrate a-endosulfine22 (ENSA) and 
attenuated proliferation in MC-GWL expressing MEFs, but not in WT-GWL expressing cells. 
Together, these data support expanding the AS-kinase inhibitor tool set with “DFG-out” 
targeting ASDO inhibitors, which in combination allow for the independent targeting of at least 
two distinct kinases (Figure 1C). 
 
RESULTS AND DISCUSSION 
 
Approaches utilized to expand analog-sensitive kinase technology. The starting 
point of this study was an effort to develop an AS-version of microtubule-associated Ser/Thr 
kinase-like (MASTL) protein, commonly known as GWL, in order to investigate its mitotic 
functions and role in the cell cycle23. Over-expression and immunoprecipitation of FLAG-
tagged GWL constructs provided a means to assess the activity of a cohort of GWL mutants 
(Figure 2A). This assay demonstrated that GWL is an ‘intolerant’ kinase evidenced by the 
inactivity of the AS1 (M110G) and AS2 (M110A) GWL kinase alleles (Figures 2B-C & S1A), 
and neither sogg mutations nor the ES-kinase approach were capable of generating an AS-
GWL system (Figure S1A-G). In the first instance, we decided to make sogg mutations at the 
analogous positions in GWL, which included mutations that were previously successful for 
kinases such as Pto (L68I), APH(3’)-IIIa (N268T) and GRK2 (S268V) (Figure S1G)10. Only 
one of these mutations, V61I-GWL, augmented GWL activity, evidenced by increased myelin 
basic protein phosphorylation, but did not restore activity of the double mutant V61I/M110A-
GWL (Figure S1B). Bioinformatically, we identified sites in the G-loop consensus sequence 
(GxGxxG) that deviated from other AGC kinases, but reversion mutations in the G-loop, made 
to adopt the more common amino acids, had a meagre (S42G) to no (S42G/A45S) effect in 
combination with M110A-GWL (Figure S1A-C)24. 
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Figure 2. Systematic mutational analysis of the GWL gatekeeper position. A) General 
workflow for the immunoprecipitation-mediated kinase assay. B,C) Systematic analysis of 
gatekeeper mutations in the GWL ATP-binding pocket. D) Rescue of RNAi-mediated GWL 
depletion by co-expression with siRNA-resistant WT- and MC-GWL constructs (WTr- and 
MCr-GWL). E-I) FACS-cell cycle analysis of HeLa cells.  Kinase assays were performed at 
least 3-times per mutation and quantitation using ImageJ (1.47v) (densitometry) of the average 
normalized % kinase activity (pENSA:GWL ratio used as a readout of kinase activity) ± S.D. 
was performed and plotted using Prism 6.0. 
 
Initial efforts to identify sogg mutations for Ala-gatekeeper GWL were unsuccessful, and thus 
we hypothesized that other small amino acids, presumably preserving an expanded 
hydrophobic ATP-binding pocket, might be useful in combination with previously identified or 
new sogg mutations. To explore this idea further, the gatekeeper position was scanned with 
relatively small amino acids, which led to the discovery that MC-GWL-mediated 
phosphorylation of ENSA was only 4-fold less compared to WT (Figure 2B – C). Furthermore, 
through FACS analysis, we showed that RNAi-resistant MC-GWL, unlike M110A-GWL, was 
able to restore G1, S and G2/M cellular levels to the same extent as an siRNA-resistant WT 
rescuing plasmid in GWL depleted HeLa cells (Figures 2D – I & S2A – F). This result inspired 
the generation of an ES-kinase system; however, the electrophilic inhibitors AG1-2 and FMKB-
PP1 (Figures 1E, S1D & E and S2), which were validated against T338C-c-Src, did not 
robustly inhibit MC-GWL at 20 µM concentrations (Figure S1D – E)9. Of the other small 
gatekeeper mutations, M110T-GWL displayed ~8% activity compared to WT, and thus we 
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made Cys mutations in an M110T-GWL mutant to mimic the cysteines in the hinge regions of 
EphB3 (C717) and EGFR (C797); M110T/G116C and M110T/D117C13, 15. In combination with 
a Thr gatekeeper, similar mutations in EphB1 (G703C) and c-Src (S345C), to name a few, are 
targetable using electrophilic quinazoline-based inhibitors (e.g. AQZ, Figure 1D), but due to 
the inactivity of these GWL double mutants, we were not able to apply them (Figure S1F – 
G)13, 15. 
 
AD57-analogs specifically target MC-GWL in vitro. Due to the inefficacy of known ES-
kinase inhibitors against MC-GWL, we decided to generate novel inhibitors based on the 
structure of AD5725 (Figures 3A & S3). We surmised that replacement of the urea linker with 
an acrylamide linker might allow selective targeting by a nucleophilic Cys-mutant16. AD57 also 
seemed like an ideal candidate as it selectively inhibited MC-GWL with an IC50 value of 10.6 
± 0.4 µM and displayed no inhibitory activity against WT-GWL (Figure 3B & D). ASDO1, the 
first in a series of AD57-analogs, was synthesized by coupling of an anilinopyrazolopyrimidine 
with a 3-benzoylacrylic acid chloride (Supplemental Schemes 1 – 3 & Fig. 4A)9, 26. The 
resulting compound contained an acrylamide linker bridging the pyrazolopyrimidine moiety 
with a trifluoromethylbenzoyl group. This feature is similar to a trifluoromethylphenyl group, 
which is commonly incorporated into some type II kinase inhibitors19, 27. ASDO1 (Analog-
Sensitive “DFG-Out” kinase inhibitor-1) (Figure 3A) completely abrogated MC-GWL activity at 
a concentration of 20 µM without inhibiting WT-GWL (Figure S3). By assaying AD57 and 
ASDO1 more rigorously using the immunoprecipitation-based kinase assay with ENSA as 
substrate, we were able to show that ASDO1 exhibited a >60-fold improvement in potency 
against MC-GWL with an IC50 value of 0.17 ± 0.09 µM and remained exquisitely selective for 
MC- vs. WT-GWL even up to concentrations as high as 100 µM (Figures 3C – D, 4A & S4A – 
B).     
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Figure 3. Establishing the inhibitory activity of AD57 and ASDO1 in the GWL kinase 
assay.  A) Chemical Structures of AD57 and ASDO1. Structural features highlighted in Green 
are linkers that bridge the PP1 moiety with the terminal trifluoromethylphenyl (Red) group.  B-
C) FLAG-tagged WT- and MC-GWL kinase assays in the presence of increasing 
concentrations of AD57 (B) or ASDO1 (C). D) Kinase activity was quantitated using ImageJ 
(1.47v) (densitometry) and reported as the average normalized % kinase activity ± S.D. 
 
Structural studies using an AD57-c-Src co-crystal structure predicted that formal halogenation 
of the terminal phenyl ring with ortho-fluorine and para-chlorine substituents would fine-tune 
the selectivity profile of AD57. Indeed, these halogenated AD57-derivatives maintained 
inhibitory activity toward Ret, Raf, Src and S6K, reduced mTor inhibition and led to significantly 
less toxicity in a multiple endocrine neoplasia type 2 Drosophila model system25. In an attempt 
to fine-tune the selectivity of ASDO1 toward MC- vs. WT-GWL, we synthesized halogenated 
and bulkier, non-halogenated ASDO-derivatives by first incorporating acetophenones into the 
microwave-assisted aldol-condensation with glyoxylic acid to yield 3-benzoylacrylic acids26, 
which after conversion to acid chlorides were later coupled with anilinopyrazolopyrimidines 
(Supplemental Schemes 2 – 3 & Figure 4A) to produce ASDOs 2 – 6. 
 
  
8 
ASDO2 contains a trifluoromethylbenzoyl group with a para-fluoro substituent and 
demonstrated an ~3-fold improvement in potency, whereas the effect of the para-chloro 
substitution (ASDO3) was negligible (Figures 4A – C & S4C – E). We also explored the activity 
of bulkier derivatives in hopes of improving their selectivity for Cys-gatekeeper versus WT 
kinases. Unfortunately, replacing the central benzene ring with a naphthyl (ASDO4, Figures 
4A & S4F) or 3-methylbenzyl group (ASDO5, Figures 4A & S4G) dramatically weakened 
inhibitory activity; however, the 2-methylphenyl substitution of the inner-benzene ring 
(ASDO6) in combination with the para-fluoro substitution seen in ASDO2 resulted in a 
compound with inhibitory activity almost equal to that of the ASDO1 precursor (Figures 4A, C 
– D & S4H – I). Interestingly, DO1, which lacks the pyrazolopyrimidine group, also displayed 
mono-specific targeting of MC-GWL vs. WT, but with attenuated inhibitory activity compared 
to ASDO1 (Figures 4A, C & S4J – K), suggesting that the selectivity filter resulting in Cys-
gatekeeper kinase specificity lies within the phenylbenzoylacrylamide scaffold and that the 
electrophilic olefin might be targeted by the Cys-gatekeeper residue. Furthermore, 
replacement of the trifluoromethyl group of DO1 with a para-ethoxy substituent (DO2) 
completely ablated inhibitory activity toward both WT- and MC-GWL (Figures 4A, C & S4L – 
M). Interestingly, some type II kinase inhibitors (e.g. AD57 and Sorafenib25, 27) possess a 
trifluoromethyl substituent on their terminal phenyl ring, which occupies space in an allosteric 
hydrophobic pocket unique to the inactive kinase conformation19, 28. In contrast to DO1, the 
lack of inhibitory activity of DO2 hints at the possibility that this series of compounds, like the 
parent compound AD57, might stabilize the inactive ‘DFG-out’ kinase conformation. 
 
Figure 4. In vitro analysis of ASDO-derivatives. A) The potency of synthetic AD57-
derivatives (ASDOs), DO1 and commercially available DO2 was assessed using an in vitro 
immunoprecipitation kinase assay; na = not applicable and nd = not determined. The 
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potencies of  ASDO2 (B-C) and ASDO6 (C-D) were determined using FLAG-tagged WT- and 
MC-GWL kinase assays. E) ASDO2 and ASDO6 were screened at 1µM against a panel of 50 
kinases, carefully selected to represent the kinome, using the Kinase Express Screen 
(International Centre for Kinase Profiling, University of Dundee). 
 
To establish the importance of the bulkier central ring of ASDO6, both ASDO2 & 6 were 
subjected to a rigorous kinase inhibition-profiling screen (International Centre for Kinase 
Profiling, University of Dundee Kinase Profiling Express Screen). At 1 µM, ASDO2 inhibited 
15 of 50 kinases with inhibitory activity ≥ 60% (60 – 95%); however, as is the case with 
classical AS-kinase inhibitors, the increased bulk of the central benzene ring of ASDO6 likely 
accounts for the decrease in number of WT-kinases targeted with inhibitory activity  > 60% 
(62 – 84%); only 4 of 50 kinases. Note that the higher end of the inhibitory range decreased 
from 95% for ASDO2 to 84% for ASDO6, providing further evidence that the bulkier ASDO6-
derivative is more refractory toward WT-kinases (Figures 4E & S5A – B). 
 
ASDO6 targets AAK and Cdk1 bearing a Cys-gatekeeper and displays orthogonality 
with WT kinases. Next, we sought to place ASDO-compounds within the pantheon of general 
AS-kinase inhibitors. To do this, we mutated the gatekeeper positions of AAK (L210) and 
Xenopus laevis Cdk1 (F80) to cysteines and subjected them to kinase assays with increasing 
concentrations of ASDO2 and/or 6 (Figures 5A – F & S6A – C). Both kinases tolerated the 
Cys-gatekeeper mutation with improved (Cdk1) or a slight reduction (AAK) in kinase activity 
compared to WT (Figure S6B – C). Moreover, ASDO2 inhibited L210C (LC)-AAK with the 
greatest potency, demonstrating an IC50 value of 25 ± 2 nM (Figures 4A, 5A & C) and was 
>70-fold selective in targeting LC-AAK vs. WT-AAK. Although less potent than ASDO2, 
ASDO6 inhibition of LC-AAK (IC50 = 1.7 ± 0.4 µM) and F80C-Cdk1 was about 10-fold more 
selective vs. their WT counterparts, respectively (Figure 5B – F). 
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Figure 5. In vitro analysis of ASDO2/6 in FLAG-AAK and Myc-Cdk1 kinase assays. The 
inhibitory activity of ASDO2 (A&C) & ASDO6 (B-C) against FLAG-tagged WT- and LC-AAK 
constructs was assessed using a radioactive kinase assay to detect 32PO4-H3 substrate. D-E) 
The inhibitory activity of ASDO6 against MYC-tagged WT and F80C-Cdk1 was assessed 
using a radioactive kinase assay for the detection of 32PO4-H1. C,F) Kinase activity was 
quantitated using ImageJ (1.47v) (densitometry) and reported as the average normalized % 
kinase activity ± S.D.  
 
ASDO2 selectively inhibits MC-GWL in cells. Although ASDO6 inhibited less WT-kinases 
with inhibitory activity >60% (Figure 4E), ASDO2 displayed greater potency and specificity in 
GWL and AAK kinase assays (Figure 4A). We, therefore, opted to assess the effects of 
ASDO2 on cellular ENSA phosphorylation and proliferation in MEFs over-expressing WT- or 
MC-GWL. To establish cellular models for MC-GWL, we decided to employ MEFs containing 
loxP sites flanking exon 4 of the murine GWL gene29. Treatment of these cells with Cre-
expressing adenovirus depleted GWL and allowed for reintroduction of human WT- or MC-
GWL cDNA via lentiviral transduction (Figure 6A). After confirming the presence of human 
GWL by western analysis, both populations of WT- and MC-GWL expressing cells were 
treated with nocodazole (200 ng/mL) for 16 – 20 h (Figure 6B). The activity of mitotic kinases 
increases substantially during mitosis, making the nocodazole-mediated mitotic arrest (M-
arrest) essential for visualizing the cellular inhibition of ENSA phosphorylation; inhibition of an 
inactive kinase would only reveal background level phosphorylation. After M-arrest and 4 h of 
2 µM ASDO2 or DMSO treatment, cells were harvested, lysed and probed with anti-phospho-
ENSA (pENSA) antibody by western blot analysis, revealing mono-specific inhibition of MC-
GWL-mediated ENSA phosphorylation (Figure 6C – D). Functionally, GWL has been linked to 
cellular proliferation in several studies, and thus serves as an ideal gauge for GWL activity20, 
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21. After 5 d of growth in the presence of inhibitor or DMSO, we observed that only cells 
depleted of endogenous WT-GWL and over-expressing MC-GWL had dramatically reduced 
proliferation in an ASDO2 concentration-dependent manner, thus confirming the utility of 
ASDO2 and possibly other ASDO-derivatives in cellular models (Figure 6E). 
 
Figure 6. Cellular analysis of ASDO2 in WT- and MC-GWL expressing mouse embryonic 
fibroblasts (MEFs). A) Expression of exogenous WT- and MC-GWL confirmed by western 
analysis. B) Strategy used to fully activate GWL in MEFs. Cells were treated with 200 ng/mL 
nocodazole for 16 – 20 h before harvesting for downstream applications. C-D) Mitotic cells 
were treated with 2µM ASDO2 or DMSO for 4 h. ENSA, phospho-ENSA and tubulin levels in 
cell lysates were determined by western analysis. All experiments were repeated thrice and 
activity (pENSA:ENSA ratio) was quantitated using ImageJ (1.47v) (densitometry), normalized 
to DMSO control and reported as the average fold induction relative to DMSO control (without 
nocodazole) ± S.D. E) CellTiter Blue Proliferation assays. 
 
ASDO2 displays relatively slow-on and -off kinetics. At this point, it was still unclear how 
ASDO2/6 mono-specifically targeted MC- vs. WT-GWL (i.e. as a type I or II inhibitor) and the 
presence of an electrophilic, doubly-activated olefin brings to question whether or not it 
interacts with MC-GWL in a reversible or irreversible manner. To further probe the mechanism 
of action of ASDO2, we investigated the reversibility of inhibition in comparison to a type I 
inhibitor (staurosporine) and the parent type II inhibitor AD57; note that type I inhibitors 
generally display fast-on/fast-off binding/dissociation kinetics, whereas type II inhibitors 
generally display  slow-on/slow-off binding/dissociation kinetics28, 30.  
 
Initially, a washout experiment  with MC-GWL supported the notion of an ES-kinase model 
system. Evidence for this is seen by the failure of ASDO2-treated (10 µM) MC-GWL to regain 
activity after 5 washes over a 4 h period compared to the quick reactivation of staurosporine 
(STP)-treated (50 µM) MC-GWL under the same conditions (Figure 7A – C). However, when 
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we probed reactivation of MC-GWL after longer periods of time following washout of ASDO2 
and AD57 (bona fide type II inhibitor), it became evident that MC-GWL regained activity over 
time, but this reactivation period took longer due to a relatively slower off-rate (Figure 7D – E). 
Importantly, activity may not have rebounded to levels demonstrated by fully active MC-GWL 
(not treated with inhibitor) due to decomposition or destabilization of the protein over a 24 h 
period. Additionally, ASDO2 rapidly inhibited MC-GWL activity, but with a slight difference in 
inhibitory activity between 20- and 60-minute compound pre-incubation periods (Figure 7F). 
Taken together, these data suggest that ASDO2 shares similar slow-off binding-kinetics as 
the type II inhibitor AD57, but could also be acting, to a small extent, in an irreversible manner 
as inhibition marginally improves over time (Figure 7F). Unfortunately, expression, purification 
and X-ray crystallography of full-length GWL has proven to be a major technical challenge; 
therefore, to pin down the exact binding mode of ASDOs in GWL, technical innovations in 
GWL structural biology are required20.  
 
 
Figure 7. Comparing binding kinetics of ASDO2 to type I/II kinase inhibitors 
staurosporine (STP, type I) and AD57 (type II).  FLAG-tagged MC-GWL was treated with 
DMSO (A – F), ASDO2 (A,C & D), STP (B,C) or AD57 (E) for 20 minutes and then subjected 
to GWL kinase assay conditions. These beads were also subjected to several washes (buffer 
exchange) for the indicated amount of time before start of the kinase assay (A – F).  F) Kinases 
assays were performed with FLAG-tagged MC-GWL, pre-incubated with DMSO or ASDO2 for 
20 or 60 m before start of the kinase reaction; reaction started by addition of ATP and ENSA. 
All experiments were repeated thrice and the average pENSA/FLAG(M110C-GWL) ratio was 
quantitated using ImageJ (1.47v) (densitometry) and normalised to DMSO control (C). 
 
ASDO2/6 demonstrates a type II inhibitor binding mode with LC-AAK. To cement the 
binding-mode of ASDO2/6,  we solved X-ray co-crystal structures with LC-AAK31. Both 
compounds were sandwiched between the N- and C-terminal lobes bound to the ATP-binding 
pocket, making the expected interactions with the backbone of the hinge region (Glu211 and 
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Ala213) and stretching all the way to the Ca-helix, displacing it in comparison to the WT-AAK 
ADP-bound structure (PDB: 4CEG, Figure  S7A – D). In both cases, the DFG-motif aspartic 
acid residue adopts an ‘out’ conformation (DFG-out), in which Phe275 points into the ATP-
binding pocket, while the terminal aromatic groups of both compounds are buried in 
hydrophobic pockets adjacent to the Ca-helix, indicative of type II kinase inhibitors (Figures 
8A, B & S6D)19. In fact, overlay of the Asp274 residues of the 1NM-PP1- (type I, PDB: 4LGH) 
and ASDO2/6- (type II) bound structures illustrates a key difference between type I and II 
inhibitors: The Asp residue flips 180o going from an active to an inactive conformation, allowing 
Phe to pack against ASDO6 (Figures 8A, B & S7D). 
 
 
Figure 8. X-ray co-crystal structures of ASDO2 and ASDO6 with LC Aurora-A kinase. A)  
Alignment of ASDO6, ADP (4CEG) and 1NM-PP1 (4LGH) bound structures reveals the 
orientation of their respective catalytic-motif aspartic acid residues. B) A zoomed-in view of 
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panel (A). C) ASDO6 abuts the gatekeeper cysteine residue forming a weak electrostatic 
interaction with the thiol hydrogen of cysteine and a stronger hydrogen-bonding interaction 
with the backbone of Ala273, serving to clamp ASDO6 within the nucleotide binding-site 
proximal to the gatekeeper position. D) Comparison of the ASDO2- and ASDO6-bound LC-
AAK structures. E) A zoomed-in view of panel (D). F) Superimposition of the ASDO6- and 
ADP-bound structures reveals a potential conflict between the ASDO6-amide and the 
hydrophobic L210 gatekeeper residue. G,H) ASDO6 (G) and 3MB-PP1 (H) inhibitory activity 
was assessed against M110A-GWL and MC-GWL respectively using the immunoprecipitation 
kinase assay. 
 
In the ASDO6-bound structure, Cys210 appears to form a weak, electrostatic interaction with 
the amide ‘N’, and the Ala273 backbone carbonyl forms a strong hydrogen bond with the same 
amide group, serving as a molecular clamp that also brings to light the importance of the 
cysteine residue (Figure 8C). Comparing the ASDO2- and 6-bound structures also sheds light 
on the molecular level basis for the decrease in WT-kinase targeting by ASDO6; that ASDO6 
prefers binding to AAK only when the gatekeeper residue is a polar amino acid such as 
cysteine. Alignment of these structures shows that the methylphenyl ring of ASDO6 twists in 
the direction of Cys210, bringing the amide closer to the Ala273 backbone; however, a water 
molecule fills the gap between ASDO2, Cys210 and the Ala273 backbone with all three 
elements forming a hydrogen-bonding network in the ASDO2-bound structure (Figures 8D, E 
& S7E).  
 
As a result of placing the polar amide group of ASDO6 in closer proximity to the gatekeeper 
residue, WT AAK, which harbors a hydrophobic Leu210 gatekeeper residue, would disfavor 
and destabilize the ASDO6-bound conformation (Figure 8F). Based on this hypothesis, other 
hydrophobic amino acids such as Ala should also attenuate ASDO6 inhibitory activity and 
replacing cysteine with a less polar amino acid or with Gly, which lacks a side-chain, should 
abolish the molecular clamp mechanism and abrogate the ASDO6-GWL interaction as well. 
To test these hypotheses, we over-expressed, immunoprecipitated and treated FLAG-M110A-
GWL with ASDO6 up to a concentration of 10 µM. As predicted, ASDO6 was not able to inhibit 
M110A-GWL, nor was 3MB-PP1 able to inhibit M110C-GWL in vitro (Figure 8G & H), 
suggesting the two systems work independently of each other and could be used to 
differentially inhibit other combinations of kinases based on gatekeeper mutations to either 
cysteine or Ala/Gly.  
 
Discussion and Conclusions 
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AS-kinase technology has been employed to dissect the cellular functions of individual kinases 
across the kinase family, but there are still a number of kinases that remain averse to this 
methodology. In order to apply AS-kinase technology, mutations that engender sensitivity to 
pharmacologic inhibition must also maintain sufficient kinase activity so that the mutant kinase 
can recapitulate WT cellular function. There are many ways to broaden the scope of AS-kinase 
technology such as making sogg mutations that rescues the activity of ‘intolerant’ kinases 
when an Ala/Gly-gatekeeper mutation is present10. Also, over the years, a number of different 
AS- and ES-systems have been developed that incorporate amino acids other than Ala or Gly, 
e.g. Cys or Thr9, 13, 17, 18, into the gatekeeper position, but so far, these systems have not been 
widely utilized in the field; though some are still in their infancy. In terms of AS-systems that 
have proven fruitful, a number of new reagents such as staralogs7 offer even greater specificity 
and potency, but to expand the scope of AS-kinase technology further we need not focus 
solely on engineering inhibitors against the active kinase conformation, but take full advantage 
of all modes of pharmacologic inhibition. To date, type II inhibitors have been left out of the 
loop when it comes to the development of chemogenomic technology, but this study is the first 
to provide an example of a chemical genetic system based on Cys-mutant kinase inhibition 
with a type II inhibitor; a system that we now refer to as the ASDO (Analog-Sensitive ‘DFG-
Out’)-kinase system (Figure 1B & C). 
 
Furthermore, type I and II kinase inhibitors bind to disparate kinase conformations resulting in 
their catalytic inactivation19, 27, 28. Due to evolutionary pressure to preserve the catalytically 
active kinase conformation, type I inhibitors encounter a very similar ATP-binding pocket 
across the kinome, made exploitable through the ‘bump-hole’ method. The inactive kinase 
conformation is not bound by this evolutionary pressure and is more varied28, which may have 
hampered previous attempts to generate a type II inhibitor-based ASDO-kinase system. 
Despite this variability, we systematically optimized the ASDO-scaffold to engender a small-
molecule inhibitor that displays generality across at least three divergent Ser/Thr-kinases 
bearing a Cys-gatekeeper, so far, and ASDO2/6 display bio-orthogonality versus WT kinases 
(Figures 1B & 4F). As this system not only appears to take advantage of steric 
complementarity, but also electrostatic interactions, to engender specificity toward Cys-
gatekeeper kinases, we hypothesized that it may act independently of the canonical AS-kinase 
system, which is based solely on steric complementarity. This theory was validated in vitro 
and will likely change the landscape of future studies involving signaling pathways in cells and 
disease models. These multiple AS/ASDO-kinase systems along with the Ele-Cys and ES-
kinase systems (systems that utilize electrophilic-quinazoline and 5’-electrophilic adenosine 
scaffolds) now provide an ensemble of chemical genetic tools to explore differential and 
independent kinase inhibition across at least two kinases in cells.
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Lastly, this system exploits binding to and stabilizing the ‘DFG-out’ conformation of kinases 
and we demonstrated the tenability of isolating these ASDO-co-crystal structures using X-ray 
crystallography. To date, X-ray crystal structures of inactive kinase conformations across the 
kinome are sparse19, 28, but the ASDO system could potentially be used to generate X-ray 
crystal structures of other inactive kinase conformations. This technology, therefore, has great 
potential to galvanize drug discovery efforts by providing new ‘DFG-out’ X-ray crystal 
structures that would assist with rational, in silico drug design efforts. 
 
METHODS 
Kinase Assays 
Immunoprecipitation and radioactive kinase assays were carried out as published 
previously20. The catalytically dead mutant D174A-GWL was used as a control for inhibition. 
Aurora-A and xlCDK1 assays were carried out similarly to FLAG-GWL immunoprecipitation 
kinase assays. N-terminally tagged FLAG-Aurora-A32 kinase and C-terminally tagged MYC-
xlCDK1 were over-expressed in HEK 293T cells using the standard phosphate-mediated 
transfection method. Cdk1 assays were carried out by incubating HEK 293T lysates containing 
MYC-CDK1 with 4 µg of anti-c-Myc antibody and immunoprecipitation with 5 µl of 
Dynabeads™ Protein G (Thermofisher). To detect phosphorylated histones H1 (CDK1, Fig. 
S5A) and H3 (1µg/20µl reaction (AAK)) the standard kinase reaction was spiked with 0.075 
MBq  g-32P ATP (PerkinElmer, Seer Green, UK) per 20 µl reaction. After the reaction was 
stopped with 5 µl 5X SDS loading buffer and boiled for 5 min at 95 °C, the mixture was resolved 
via SDS-PAGE (4-15% Criterion pre-cast gels; Bio-Rad Laboratories, Hemel Hempstead, UK, 
or 13% SDS-polyacrylamide gels). Staining with coomassie-blue revealed ~28 and 21 kDa 
bands respectively that were imaged by autoradiography. All concentration-dependent kinase 
assays were performed thrice and quantitation of activity (Phospho-signal:kinase loading ratio) 
using ImageJ (1.47v) (densitometry) of the average normalised % kinase activity ± S.D. was 
plotted using Prism 6.0. Non-linear regression using Prism 6.0 was used to calculate IC50 
values.   
 
Crystallisation and Data Collection 
Aurora-A (containing mutations L210C, C290A and C393A)31 was co-crystallised with ASDO2 
and ASDO6 by mixing purified protein (500 µM) with compound (ASDO2, 500 µM; ASDO6, 
1mM) in a 1:1 protein:ligand ratio, before setting up sitting drop vapour diffusion experiments 
at 22 °C; where 0.25 μl of complex was mixed with 0.25 µl of crystallisation buffer and 
equilibrated against a well volume of 50 µl.  
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Crystals of Aurora-A bound to ASDO2 were obtained in condition F6 of the PEGs II Suite (0.2 
M ammonium sulfate, 0.1 M tri-sodium citrate pH 5.6, 25 % w/v polyethylene glycol 4000; 
Qiagen, USA) and bound to ASDO6 in condition A1 of the JCSG+ Suite (0.2 M lithium sulfate, 
0.1 M sodium acetate pH 4.5, 50 % w/v polyethylene glycol 400; Qiagen, USA). No additional 
cryo-protectant was added as the crystals were deemed already cryo-protected from their 
crystallisation conditions. The crystals were cryo-cooled in liquid nitrogen and no ice formation 
was observed. Diffraction data to 2.4 Å (ASDO2) and 2.1 Å (ASDO6) resolution were collected 
at the Diamond Light Source [DLS, Didcot, UK] on beamline I04. 
 
Phasing, Model Building and Refinement 
All diffraction data were collected at 100K. Autoprocessed datasets were generated by 
automatic integration of the data using the software package XDS followed by processing 
using the Pointless and Scala programs from the CCP4 software suite.   Phases were 
obtained by molecular replacement using Phaser with a high resolution structure of ADP-
bound Aurora-A C290A,C393A (PDB: 4CEG) used as the search model.  An iterative 
combination of manual building in Coot and refinement with Phenix.refine produced the final 
model. The protein crystallised in spacegroups P3221 (ASDO2) and P6122 (ASDO6), with a 
single molecule comprising the asymmetric unit. 
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Table 1:  Crystal data and structure refinement (ASDO2) 
Resolution range (É) 76.88  - 2.4 (2.486  - 2.4) 
Space group P 32 2 1 
Unit cell 88.769 88.769 77.28 90 90 120 
Total reflections 28217 (2745) 
Unique reflections 14112 (1373) 
Multiplicity 2.0 (2.0) 
Completeness (%) 100.00 (100.00) 
Mean I/sigma(I) 23.07 (4.63) 
Wilson B-factor 57.84 
R-merge 0.01263 (0.1532) 
R-meas 0.01786 
CC1/2 1 (0.93) 
CC* 1 (0.982) 
R-work 0.2022 (0.2668) 
R-free 0.2354 (0.3553) 
Number of non-hydrogen atoms 2054 
macromolecules 1993 
ligands 43 
water 18 
Protein residues 255 
RMS(bonds) 0.013 
RMS(angles) 1.33 
Ramachandran favored (%) 90 
Ramachandran outliers (%) 2.8 
Clashscore 13.13 
Average B-factor 74.4 
macromolecules 74 
ligands 97 
solvent 69.2 
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Supplementary Figures 
Supplementary figures in support of this manuscript can be found in the Supporting 
Information. 
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Table 2:  Crystal data and structure refinement (ASDO6) 
 
Resolution range (É) 71.04  - 2.13 (2.206  - 2.13) 
Space group P 61 2 2 
Unit cell 82.027 82.027 172.609 90 90 120 
Total reflections 39980 (3856) 
Unique reflections 19990 (1928) 
Multiplicity 2.0 (2.0) 
Completeness (%) 99.94 (99.33) 
Mean I/sigma(I) 17.84 (1.51) 
Wilson B-factor 44.14 
R-merge 0.03359 (0.7864) 
R-meas 0.0475 
CC1/2 0.999 (0.427) 
CC* 1 (0.774) 
R-work 0.2086 (0.3889) 
R-free 0.2682 (0.3975) 
Number of non-hydrogen atoms 2193 
macromolecules 2037 
ligands 80 
water 76 
Protein residues 256 
RMS(bonds) 0.011 
RMS(angles) 1.11 
Ramachandran favored (%) 96 
Ramachandran outliers (%) 0.4 
Clashscore 6.46 
Average B-factor 60.8 
macromolecules 59.7 
ligands 87.9 
solvent 61.6 
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Supplementary Figures 
 
 
Figure S1. Attempts to identify rescuing sogg mutations and establish an ES-kinase system for 
Greatwall kinase. A) FLAG-tagged GWL or mutants D174A, M110G and the double and triple mutants 
M110C/V94A, M110A/S42G and M110A/S42G/A45S were expressed in human HEK 293T cells, 
immunoprecipitated and taken into kinase assays using ENSA as substrate.  B) FLAG-tagged GWL or 
mutants Y59V, Y59T, V61I, Y106V, Y107T, M110A and double mutant M110A/V61I were expressed in 
human HEK 293T cells, immunoprecipitated and taken into kinase assays using myelin basic protein as 
substrate. C) Alignment of the glycine-rich loop region of GWL with those of other AGC kinases such as 
PKC isoforms e, b2 and i reveals incongruous amino acids at positions S42 and A45 of GWL. D,E) 
Analogue-sensitive, electrophilic kinase inhibitors AG1-3 (D) were tested against immunoprecipitated 
WT and M110C GWL (E) in kinase assays using ESNA as substrate. F) FLAG-tagged GWL or mutants 
D174A, M110T and double mutants M110T/G116C and M110T/D117C were expressed in human HEK 
293T cells, immunoprecipitated and taken into kinase assays using ENSA as substrate. G) Diagram 
illustrating sogg mutations made within b-sheets 2 – 4 and mutations of the gatekeeper position and 
select hinge region amino acids to cysteine. Mutations Y59V and Y59T were rationally incorporated 
particularly due to the stabilising effect of b-branched amino acids on b-sheets.   
 
 
Figure S2. Cell cycle analysis of HeLa cells expressing siRNA-resistant GWL constructs. A) 
Rescue of RNAi-mediated GWL depletion by co-expression with siRNA-resistant WT (GWL)-, M110A- 
and MC-GWL constructs (GWLr = WT, M110Ar and M110Cr). B-F) FACS-cell cycle analysis of HeLa 
cells.   
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Figure S3. Screen of AD57-analogues against WT- and M110C-GWL. FLAG-tagged GWL and 
M110C mutant were expressed in human HEK293T cells, immunoprecipitated and taken into kinase 
assays in the presence of 20 µM concentrations of AD57-analogues 56, 82, 88, 100, 102 (ASDO1), 262 
and AG1-2 and FMKB-PP1 (AG3) using ENSA as substrate. 
 
Figure S4. In vitro analysis of ASDO analogues by IP kinase assay and western analysis. A-M) 
FLAG-tagged GWL and M110C mutant were expressed in human HEK 293T cells, immunoprecipitated 
and taken into kinase assays in the presence of increasing concentrations of ASDO analogues and DO1 
and DO2 using ENSA as substrate. 
 
 
Supplemental Scheme 1. Synthetic route for nitrophenyl (or nitrophenylmethyl) pyrazolopyrimidine 
intermediates. 
 
Supplemental Scheme 2. Synthetic route for 3-benzoylacrylic acids. 
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Supplemental Scheme 3. Synthesis of ASDO1-6 by coupling of pyrazolopyrimidines with 3-
benzoylacrylic acids. 
 
 
Figure S5. Kinase Profiling Express Screen. ASDO2 (A) and ASDO6 (B) were tested against 50 
select kinases at a concentration of 1 µM. The Kinase Profiling Express Screen was conducted at the 
International Centre for Kinase Profiling, University of Dundee. 
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Figure S6. xlCDK1 and Aurora A kinase assays. A) In order to establish an xlCDK1 kinase assay, 
MYC-tagged xlCDK1 and F80C mutant were expressed in HEK293T cells, immunoprecipitated with 4 
µg of anti-MYC antibody and 5 µL Protein G magnetic Dynabeads and taken into radioactive 32P-ATP 
kinase assays with increasing amounts of the substrate histone H1. B) After optimisation of the xlCDK1 
kinase assay, WT and F80C mutant xlCDK1 were assayed again to establish the relative activity of the 
mutant vs. WT kinase, revealing the mutant was significantly more active than WT. C) FLAG-tagged WT 
and L210C Aurora A kinase (AAK) were expressed in HEK293T cells, immunoprecipitated and taken 
into radioactive 32P-ATP kinase assays using histone H3 as substrate. L210C-AAK demonstrated 
significant activity compared to GFP expressing cells, but slightly less activity than WT AAK.  
   
 
Figure S7.  X-ray co-crystal structures of ASDO6 and ASDO2 help reveal the molecular level basis 
for cysteine-gatekeeper specificity. A) The final 2mFo-DFc electron density map is shown as a mesh 
contoured at 1 σ with ASDO6 bound to the ATP-binding pocket and stretching from the hinge to the Ca-
helix. B) ASDO6 makes the expected interactions with the hinge region of Aurora-A kinase, typical of an 
ATP-competitive inhibitor. P-loop has been removed for clarity. C) Front view (left panels) of compound 
ASDO6 (purple) and ADP (pink) showing the Cα-helix and end view (right panel) of the Cα-helix in 
ASDO6 structure (green) and ADP structure (cyan, PDB: 4CEG). D) ASDO2-bound Aurora A kinase is 
in the DFG-out conformation as expected with a type II inhibitor. Compound is bound adjacent to Cα-
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helix, distorting it. E) Water-mediated hydrogen bonds between ASDO2, the carbonyl of Ala273 and the 
side-chain of Cys210. 
 
 
Supplementary Methods 
 
Antibodies and Western Analysis  
Mouse monoclonal anti-FLAG® M2 and rabbit anti-MASTL (GWL, Prestige Antibodies) antibodies were 
purchased from Sigma-Aldrich and polyclonal rabbit anti-phospho(Ser67)-ENSA/ARPP19 and anti-
ENSA antibodies were purchased from Cell Signaling Technology. Mouse monoclonal anti-c-Myc 
(9E10) and mouse and rabbit derived antibodies for loading controls a-tubulin (DM1A) and GAPDH 
respectively were purchased from Abcam. Secondary antibodies were HRP-conjugated, polyclonal 
goat-derived antibodies against mouse and rabbit (Dako, Agilent Technologies). Western blot analysis 
of GWL, ENSA, phospho-ENSA, and the loading controls a-tubulin and GAPDH was accomplished 
through SDS-PAGE of cell lysates in 1X SDS-loading buffer containing β-mercaptoethanol (5X buffer: 
0.25 % w/v Bromophenol blue, 0.5 M DTT, 50% v/v glycerol, 10% v/v SDS (sodium dodecyl sulphate) 
and 0.25M Tris-HCl pH 6.8) and transfer of protein onto PVDF using the Trans-Blot Turbo System (Bio-
Rad). Quantitation of western blot protein intensity was performed by densitometry using ImageJ and 
data were plotted using Prism 6.0. 
 
Expression Constructs  
The mammalian expression construct for N-terminally FLAG-tagged full-length human GWL and 
Aurora A kinase have previously been described30-31. The plasmid for expression of Xenopus laevis 
MYC-Cdk1 was a kind gift from Helfrid Hochegger.  Recombinant His-tagged ENSA was purified using 
Ni-NTA agarose (QIAGEN) from BL21 E. coli following the manufacturer’s recommended protocol. 
FLAG-GWL (WT or M110C) was cloned into the pLVX-IRES-Puro (Clontech) lentiviral vector through 
restriction digestion of the FLAG-GWL construct with NotI and ligation of this product with NotI digested 
and phosphatase (CIP) treated pLVX-IRES-Puro plasmid. Ligation with T4 DNA Ligase (NEB) 
proceeded at 15 oC overnight after which 2 ul was transformed into supercompetent DH5 . After 
plating and growing transformants overnight, colonies were selected, amplified in the presence of 
ampicillin and then harvested to prepare DNA minipreps. Miniprepped DNA was digested with BamHI 
and analysed by agarose gel electrophoresis to confirm that GWL expressing pLVX clones contained 
properly oriented inserts. Clones were then amplified and used to prepare lentiviral particles according 
to the instructions in the Lenti-XTM Lentiviral Expression System Manual (Clontech). 
 
Mutagenesis 
All mutagenesis reactions were carried out using the QuikChange II Site-Directed or Lightning Multi 
Site-Directed Mutagenesis Kits (Agilent) according to the manufacturer’s instructions. All plasmids 
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were sent to GATC Biotech for Sanger sequencing to confirm the mutations. Mutagenic primers were 
purchased from Eurofins and are listed below. 
GWL 
Y59V:   F – GAA AGG CGG CAA ATT GGT TGC AGT AAA GGT TG, 
            R – CAA CCT TTA CTG CAA CCA ATT TGC CGC CTT TC  
Y59T:   F – GAA AGG CGG CAA ATT GAC TGC AGT AAA GGT TG, 
            R – CAA CCT TTA CTG CAG TCA ATT TGC CGC CTT TC 
V61I:   F – GGC AGA AAG GCG GCA AAT TGT ATG CAA TAA AGG TTG, 
R – CAA CCT TTA TTG CAT ACA ATT TGC CGC CTT TCT GCC 
Y107V: F – GCA GTC TGC AAA CAA TGT CGT CTT GGT AAT GG, 
     R – CCA TTA CCA AGA CGA CAT TGT TTG CAG ACT GC 
Y107T: F – GCA GTC TGC AAA CAA TGT CAC CTT GGT AAT GG, 
R – CCA TTA CCA AGG TGA CAT TGT TTG CAG ACT GC 
D174A:  F – GGGTCATATTAAACTGACGGCTTTTGGCCTTTCAAAAGTTAC, 
  R – GTAACTTTTGAAAGGCCAAAAGCCGTCAGTTTAATATGACCC 
M110V: F – CAATGTCTACTTGGTAGTGGAATATCTTATTGGGG,  
              R – CCCCAATAAGATATTCCACTACCAAGTAGACATTG  
M110T: F – GTCTACTTGGTAACGGAATATCTTATTGGGGG, 
R – CCCCCAATAAGATATTCCGTTACCAAGTAGAC  
M110C: F – GTCTACTTGGTATGCGAATATCTTATTGGG, 
  R – CCCAATAAGATATTCGCATACCAAGTAGAC 
M110S: F – CAAACAATGTCTACTTGGTATCGGAATATCTTATTG, 
  R – CAATAAGATATTCCGATACCAAGTAGACATTGTTTG 
M110A:  F – CAATGTCTACTTGGTAGCGGAATATCTTATTGGGG,  
              R – CCCCAATAAGATATTCCGCTACCAAGTAGACATTG 
M110G: F – CAATGTCTACTTGGTAGGGGAATATC, 
  R – CAATAAGATATTCCCCTACCAAGTAGACATTGTTTG 
V94A:  F – CATTCATTGCCCATTTGTATTATTCACTG, 
  R – CAGTGAATAATACAAATGGGCAATGAATG 
S42G:  F – CATAGTGAAGCCCATTGGCCGGGGCGCCTTCG, 
  R – CGAAGGCGCCCCGGCCAATGGGCTTCACTATG 
A45S:  F – CATTGGCCGGGGCTCCTTCGGGAAAG, 
(with S42G) R – CTTTCCCGAAGGAGCCCCGGCCAATG 
G116C: F – CTTATTGGGTGTGATGTCAAG, 
  R – CTTGACATCACACCCAATAAG 
G117C: F – CTTATTGGGGGATGTGTCAAGTCTC, 
  R – GAGACTTGACACATCCCCCAATAAG 
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siRNA_ resistant GWL mutations (Figure S1):  
F – CAAAAGGACACTACTCCTTACTCTTCAAAACTCCTAAAATCATG 
R – CATGATTTTAGGAGTTTTGAAGAGTAAGGAGTAGTGTCCTTTTG 
 
Aurora-A Kinase 
L210C: F – GTCTACCTAATTTGCGAATATGCACC, 
  R – GGTGCATATTCGCAAATTAGGTAGAC  
xlCDK1 
F80C:    F – CAAGGTTGTATCTTATCTGTGAGTTTCTCTCCATGG, 
  R – CCATGGAGAGAAACTCACAGATAAGATACAACCTTG 
 
Cell Culture, Compound Preparation and FACS analysis 
MEFs and HEK 293T cells were cultured in Dulbecco’s modified Eagle Medium (DMEM) supplemented 
with 10% v/v FCS, 2 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin in a 37 °C, 5% 
CO2 incubator. For GWL depletion, 10 ul of AdCre (Vector Biolabs) was added to a 10 cm dish of MEFs 
in culture. After 3 d, cells were then treated with 500 ul of GWL expressing lentivirus (0.45 micron filtered). 
Synthetically derived ASDO compounds, 4-(4-ethoxy-phenyl)-4-oxo-but-2-enoic acid (4-ethyl-phenyl)-
amide (DO2, Sigma-Aldrich/Merck), staurosporine (Cell Signalling Technology) and AD57 were 
dissolved in DMSO and stored at -20 oC in glass vials. Cells transfected with or without GWL targeting 
siRNA (HS_MASTL_6)18 and Qiagen AllStars negative control were harvested, washed with PBS and 
fixed in 70% EtOH overnight at 4 oC. Next, cells were pelleted and washed with 1% BSA in PBS. After 
pelleting, cells were re-suspended and incubated with propidium iodide (PI) solution for at least 6 h or 
overnight (PI solution: 20  g/ml PI, 0.1% Triton X-100, 200  g ml-1 RNAse (all from Sigma) diluted in 
0.5% BSA in PBS). Cell cycle analysis was performed on the BD Accuri™ C6 Plus personal flow 
cytometer and data analysed using FCS Express 6 flow cytometry software.  
 
Proliferation Assays  
MEF cells were seeded at a density of 1000 and 2000 cells/well, respectively, in clear 96-well plates and 
allowed to grow for 5 – 6 d in the presence of inhibitors or DMSO. After the indicated time-point, all cells 
were treated with CellTiter-Blue Reagent (Promega) and allowed to incubate at 37 oC for an additional 
3 h. After 3 h, fluorescence was measured using the GloMax-Multi Detection System. All concentration-
dependent cellular proliferation assays were performed 5 times with replicates ranging from 4 to 10 per 
point and quantitation of average normalized proliferation was reported as % of the DMSO control ± S.D. 
and plotted using Prism 6.0. The t-test statistical module of Prism 6.0 was used to determine p-values 
(ns (not statistically significant): P ≤ 0.01; ***: P ≤ 0.001; ****). 
 
Chemical Synthesis 
All commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, Combi-Blocks, TCI (UK) and 
Princeton Biomolecular and were of the highest available purity. Anhydrous solvents were purchased 
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from Acros (AcroSeal) or Sigma-Aldrich (SureSeal) and were stored under nitrogen. Proton nuclear 
magnetic resonance spectra were recorded at 500 or 400 MHz on a Varian VNMRS 500 MHz 
spectrometer, at 25 °C. Carbon Nuclear Magnetic Resonance spectra were recorded at 125 MHz on a 
Varian 500 MHz spectrometer. It should be noted that we did not detect C-F heteronuclear coupling due 
to CF3 in the 
13C NMR mainly due to overlapping peaks. LCMS data were recorded on a Waters 2695 
HPLC using a Waters 2487 UV detector and a Thermo LCQ ESI-MS. Samples were eluted through a 
Phenomenex Lunar 3μ C18 50 mm × 4.6 mm column, using water and acetonitrile acidified with 0.1% 
formic acid at 1 ml/min and detected at 254 nm. The gradient employed was a 4 or 7 min. method of 5-
95% MeCN. High-resolution Mass Spectra (HRMS) were recorded at the University of Sussex Mass 
Spectrometry Centre on a high-resolution Orbitrap-XL instrument (Thermofisher). All experiments were 
carried out under an inert atmosphere of N2 unless otherwise stated. 
  
  
General procedure for the synthesis of 2-[methoxy(4-nitrophenyl)methylidene]propanedinitriles 
(1a – 1c)1. 2-[Methoxy(4-nitrophenyl)methylidene]propanedinitrile (1a) was prepared by slowly adding a 
2.0 M solution of oxalyl chloride in DCM (0.30 mL, 3.52 mmol, 1.2 eq.) to a solution of benzoic acid (0.49 
g, 2.93 mmol, 1.0 eq. ) in 15 mL DCM containing 1 drop of DMF at RT for 30 min. This solution was then 
concentrated in vacuo and then re-dissolved in 5 ml of THF containing malonitrile (0.23 g, 3.52 mmol, 
1.2 eq.) This mixture was cooled to 0 oC before drop-wise addition of DIPEA (1.28 mL, 7.33 mmol, 2.5 
eq.). This reaction was allowed to warm to room temperature before being mixed for an additional 2 h. 
Next, dimethyl sulfate (DMS, 0.33 mL, 3.52 mmol, 1.2 eq.) was added, after which the temperature was 
increased to 70 oC. This was allowed to react for 4 h before bringing the temperature down to RT. At this 
stage, the reaction proceeded overnight before being worked-up with 1 N HCl (aq.) and extracted with 
ethyl acetate. Extracts were washed with water and brine and then dried with MgSO4. The crude mixture 
was purified by silica chromatography using a hexanes/ethyl acetate solvent system (ethyl acetate 
gradient increased over time from 0 – 60%).  Concentration of the extract yielded 0.31 g (1.37 mmol, 
46%) of a yellow, oily material. 1H NMR (500 MHz, Chloroform-d) δ 7.99 (d, J = 6.5 Hz,  2H), 7.24 (d, J 
= 6.5 Hz, 2H), 4.01 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 183.8, 161.7, 132.6, 126.9, 125.8, 110.0, 49.8. 
 
2‐[Methoxy(4‐nitronaphthalen‐1‐yl)methylidene]propanedinitrile (1b) was made according to the general 
procedure reported for 1a. 1H NMR (500 MHz, Chloroform-d) δ 8.54 (d, J = 8.2 Hz, 1H), 8.25 (d, J = 7.8 
Hz, 1H), 7.94 – 7.82 (m, 3H), 7.72 (d, J = 7.8 Hz, 1H), 3.76 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 182.3, 
149.6, 130.8, 130.7, 130.7, 130.2, 126.8, 125.0, 124.2, 123.8, 122.2, 111.7, 110.4, 60.3. 
  
NO2
O OH
R
R'
i) (COCl)2, DMF (cat.), DCM
ii) Malonitrile, DIPEA, THF
iii) DMS
NO2
OMe
R
R'
NC
CN
1a - 1c
45 - 56%
Intermediate
1a
1b
1c
R     R’     %
H H 46
45
Me H 56
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2‐[Methoxy(2‐methyl‐4‐nitrophenyl)methylidene]propanedinitrile (1c) was made according to the general 
procedure reported for 1a. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 6.7 Hz, 1H), 7.52 (m, 2H), 
4.02 (s, 3H), 2.68 (s, 3H). 
 
   General 
procedure for the synthesis of 3‐(4‐nitrophenyl)‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐4‐
amines (2a – 2c)1. 3‐(4‐Nitrophenyl)‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐4‐amine (2a) was 
prepared by mixing 1a (0.31 g, 1.37 mmol, 1 eq.) with isopropyl hydrazine (0.12 g, 1.65 mmol, 1.2 eq.) 
and TEA (3.71 mL, 27.5 mmol, 20 eq.) in 5 mL of EtOH. After 1h, the reaction was concentrated and 
generation of the pyrazole was confirmed by LCMS-LCQ: 7 mins, 5-95% MeCN, Rt = 3.75 mins; [M+H]+ 
calculated for C13H13N5O2 272.11; found 272.17. The pyrazole was then diluted with 5 mL of formamide 
(0.3M 1a) and left to reflux ON at 160 oC. After cooling, the reaction was diluted with 50 mL of ice cold 
water, which was then filtered over a pad of celite. Extracting the filtrate with ethyl acetate and 
concentrating the extracts gave 190 mg (0.64 mmol, 41%) of a yellow powder that was used in the next 
reaction without further purification. 1H NMR (500 MHz, DMSO-d6) δ 8.30 (d, J = 8.7 Hz, 1H), 8.21 (s, 
1H), 7.89 (d, J = 8.5 Hz, 1H), 6.59 (s, 1H), 5.09 (hept, J = 6.7 Hz, 1H), 1.51 (d, J = 6.6 Hz, 3H). 13C NMR 
(126 MHz, dmso) δ 158.3, 155.7, 147.6, 141.4, 140.2, 129.5, 124.3, 123.9, 110.0, 30.9, 22.0. LCMS-
LCQ: 4 mins, 5-95% MeCN, Rt = 1.16 mins; [M+H]+ calculated for C14H14N6O2 299.30; found 299.17. 
 
3‐(4‐Nitronaphthalen‐1‐yl)‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐4‐amine (2b) was made 
according to the general procedure reported for 2a. After 1h of mixing 1d, isopropyl hydrazine and TEA 
in ethanol, the reaction was concentrated and generation of the pyrazole was confirmed by LCMS-LCQ: 
4 mins, 5-95% MeCN, Rt = 0.71 mins; [M+H]+ calculated for C17H15N5O2 322.12; found 321.98.  
1H NMR 
(500 MHz, DMSO-d6) δ 8.44 (d, J = 8.7 Hz, 1H), 8.37 (d, J = 7.8 Hz, 1H), 8.28 (s, 1H), 8.04 (d, J = 8.4 
Hz, 1H), 7.84 (t, 1H), 7.77 – 7.68 (m, 2H), 7.37 – 5.83 (s br, 2H), 5.14 (hept, J = 6.7 Hz, 1H), 1.53 (d, J 
= 6.7 Hz, 6H). 13C NMR (126 MHz, dmso) δ 158.2, 156.2, 153.6, 147.2, 140.6, 137.1, 133.0, 129.9, 
128.5, 127.8, 127.1, 125.4, 124.0, 122.9, 110.0, 49.0, 22.2. LCMS-LCQ: 4 mins, 5-95% MeCN, Rt = 0.74 
mins; [M+H]+ calculated for C18H16N6O2 349.35; found 349.20. 

3‐(2‐Methyl‐4‐nitrophenyl)‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐4‐amine (2c) was made 
according to the general procedure reported for 2a. After 1h of mixing 1b, isopropyl hydrazine and TEA 
in ethanol, the reaction was concentrated and generation of the pyrazole was confirmed by LCMS-LCQ: 
NO2
OMe
R
R'
NC
CN
i) Isopropyl hydrazine, EtOH
ii) Formamide, 160 oC, O.N.
2a - 2c
23 - 41%
NO2
R
R'
N
N
N
N
NH2
Intermediate
2a
2b
2c
R     R’     %
H H 41
36
Me H 23
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4 mins, 5-95% MeCN, Rt = 3.07 mins; [M+H]+ calculated for C14H15N5O2 286.12; found 286.02. 
1H NMR 
(500 MHz, DMSO-d6) δ 8.18 (s, 1H), 7.22 (s, 2H), 7.17 (d, J = 8.1 Hz, 1H), 6.73 (d, J = 8.2 Hz, 2H), 5.16 
(s, 2H), 5.01 (hept, J = 6.7 Hz, 1H), 2.12 (s, 3H), 1.46 (d, J = 6.7 Hz, 6H). LCMS-LCQ: 4 mins, 5-95% 
MeCN, Rt = 2.13 mins; [M+H]+ calculated for C15H16N6O2 313.33; found 313.17.  
 
  
General procedure for the synthesis of 3-benzoyl acrylic acids (3a – 3c)2. To prepare (2E)‐4‐oxo‐4‐
[3‐(trifluoromethyl)phenyl]but‐2-enoic acid (3a), glyoxylic acid monohydrate (2.2 g, 23.9 mmol), acetic 
anhydride (2.4 mL, 25.2 mmol) and ytterbium triflate (0.37 g, 0.59 mmol) were combined in a microwave 
reaction vial and stirred at room temperature for 10 min. Then, m-(trifluoromethyl)benzoylacetophenone 
(5 g, 24 mmol) and glacial acetic acid (4 mL) were added. The reaction vial was sealed, and the mixture 
was subjected to microwave irradiation for 10 min. at 150 W (< 6 bar internal pressure). After completion 
of the reaction, the dark brown/black mixture was diluted with water, basified with K2CO3 (25% aq.) and 
washed with DCM (5X 60 mL). Then, the aqueous phase was cooled in an ice-bath and acidified with 
HCl (concentrated aq.). The solid product was filtered off, washed with water and dried in air at 50 °C for 
24 h to give 2.3 g (39%) of a light brown solid. 1H NMR (500 MHz, DMSO-d6) δ 13.06 (s, 1H), 8.33 (d, J 
= 7.8 Hz, 1H), 8.27 (s, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.92 (d, J = 15.7 Hz, 1H), 7.80 (t, J = 7.9 Hz, 1H), 
6.71 (d, J = 15.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 194.0, 171.4, 142.2, 141.0, 138.9, 138.0, 135.7, 
135.6, 135.3, 133.2, 109.9. 
 
(2E)‐4‐[4‐Fluoro‐3‐(trifluoromethyl)phenyl]‐4‐oxobut‐2‐enoic acid (3b) was made according to the 
general procedure reported for 3a. 1H NMR (500 MHz, DMSO-d6) δ 13.17 (s, 1H), 8.43 (ddd, J = 8.1, 6.8 
(H-F), 2.2 (H-F) Hz, 1H), 8.33 (dd, J = 6.8 (H-F), 2.0 (H-F) Hz, 1H), 7.92 (d, J = 15.6 Hz, 1H), 7.71 (t, J 
= 8.5, 6.8 (H-F) Hz, 1H), 6.71 (d, J = 15.6 Hz, 1H). 13C NMR (126 MHz, dmso) δ 188.1, 166.6, 136.8, 
136.7, 136.3, 136.1, 134.2, 128.6, 118.7, 118.5, 110.0. 
 
(2E)‐4‐[4‐Chloro‐3‐(trifluoromethyl)phenyl]‐4‐oxobut‐2‐enoic acid (3c) was made according to the 
general procedure reported for 3a. 1H NMR (500 MHz, DMSO-d6) δ 13.06 (s, 1H), 8.33 – 8.31 (m, 2H), 
7.93 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 15.6 Hz, 1H), 6.72 (d, J = 15.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) 
δ 193.2, 171.3, 140.8, 140.5, 139.5, 139.0, 139.0, 137.7, 134.5, 133.1, 110.0. 
 
O
O
HO
H
+
CF3
X
O
i) Yb(OTf)3, Ac2O, 10 m
ii) AcOH, MW 150W, 10 m
3a - 3c
36 - 45%
HO
O
O
CF3
X
Intermediate
3a
3b
3c
X     %
H 39
36
Cl 45
F
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General procedure for the coupling of the 3-phenyl acrylic acids with 3-phenyl 
pyrazolopyrimidines (ASDO1-4 & 6). To a dry round bottom flask was added 2a (20 mg, 0.067 mmol, 
1.2 eq.) in 1 mL of AcOH/THF (1:1). Zn dust (13 mg, 0.20 mmol, 3.5 eq.) was added slowly and in 
portions over 5 mins. The reaction was mixed vigorously at 40 oC over the next 3 h and monitored closely 
by TLC (DCM/ethyl acetate (1:1)). Next, the reaction was diluted in ethyl acetate, filtered over a pad of 
celite and washed with water thrice. This was then washed with brine, dried with magnesium sulfate and 
concentrated in vacuo to yield a brownish solid amine (deep purple colour with ninhydrin stain). This 
amine was diluted with 500 ul of pyridine and chilled on ice before being used as a coupling partner in 
the next step. In parallel to this reaction, the conversion of the acrylic acid to an acid chloride was effected 
by combining 3a (13.7 mg, 0.057  mmol, 1 eq.) with oxalyl chloride (COCl)2 (2M in DCM, 28.5 ul, 1 eq.) 
and 1 drop of DMF (catalytic). This solution was allowed to stir for 30 min. before removal of DCM by 
roto-evaporation; the resulting acid chloride was diluted with 200 ul of DMF. This acid chloride solution 
was then slowly added to a solution of the chilled amine solution. After 10 min., the reaction was allowed 
to warm to room temperature for 30 min. and then 40 oC for 1 h. Finally, the reaction was diluted with 
ethyl acetate, washed with water and brine thrice, concentrated and purified by silica chromatography 
using a DCM/ethyl acetate solvent system (ethyl acetate gradient increased over time from 0 – 90%). To 
ensure that the remaining traces of the amine were removed, the resulting compound was purified further 
by preparatory TLC (Analtech Uniplates, Silica GF, 250 µM, 20 cm X 20 cm) under isocratic conditions 
using DCM/ethyl acetate (1:1). After etching off the correct band from the TLC plate, the silica was 
pulverised, mixed with ethyl acetate, filtered through a frit and the resulting filtrate was concentrated to 
yield 11.6 mg (0.023 mmol, 41%) of (2E)‐N‐{4‐[4‐amino‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐3‐
yl]phenyl}‐4‐oxo‐4‐[3‐(trifluoromethyl)phenyl]but‐2‐enamide (ASDO1). 1H NMR (500 MHz, DMSO-d6) δ 
10.80 (s, 1H), 8.37 (d, J = 4.5 Hz, 1H), 8.29 (s, 1H), 8.21 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.88 (d, J = 
16 Hz, 1H), 7.83 (d, J = 12 Hz, 1H), 7.81 (t, J = 4.5 Hz, 1H), 7.64 (d, J = 12 Hz, 1H), 7.25 (d, J = 16 Hz, 
1H), 6.74 (s, 2H), 5.04 (hept, J = 6.5 Hz, 1H), 1.45 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
188.2, 162.0, 157.2, 147.7, 144.3, 137.2, 136.5, 131.9, 131.9, 131.6, 131.6, 130.1, 130.1, 129.5, 129.7, 
129.1, 125.6, 125.5, 120.9, 100.3, 49.7, 21.8. LCMS-LCQ: 7 mins, 5-95% MeCN, Rt = 3.64 mins, > 99% 
purity; [M+H]+ calculated for C25H21F3N6O2 495.17; found 495.27. HRMS (ESI): [M+H]
+ calculated for 
C25H21F3N6O2 495.1678, found 495.1836. 
 
R'
R
NO2
N
N
N
N
NH2
O
X
O
HO CF3
i) (COCl)2, DMF (cat.), DCM
R'
R
HN
N
N
N
N
NH2
O
O
X
CF3
ii) Zn (dust), THF/AcOH
iii) Pyridine, 40 oC
ASDO1-4,6 (37 - 56%)
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(2E)‐N‐{4‐[4‐Amino‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐3‐yl]phenyl}‐4‐[4‐fluoro‐3‐
(trifluoromethyl)phenyl]‐4‐oxobut‐2‐enamide (ASDO2) was made according to the general procedure 
reported for ASDO1. 1H NMR (500 MHz, Chloroform-d) δ 10.29 (s, 1H), 8.58 (d, J = 4.6 Hz, 1H), 8.25 – 
8.18 (m, 2H), 7.89 (d, J = 15 Hz, 1H), 7.82 (d, J = 10 Hz, 2H), 7.57 (d, J = 10 Hz, 2H), 7.33 (d, J = 15 
Hz, 1H), 7.30 – 7.25 (m, 2H), 6.03 (s, 2H), 5.05 (hept, J = 6.5 Hz, 1H), 1.48 (d, J = 6.5 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 190.8, 156.9, 153.7, 150.4, 146.9, 143.7, 143.5, 139.3, 138.0, 134.7, 131.6, 129.0, 
128.9, 128.5, 120.6, 120.6, 120.0, 117.7, 117.5, 100.2, 39.4, 20.8. LCMS-LCQ: 4 mins, 5-95% MeCN, 
Rt = 0.62 mins, > 99% purity; [M+H]+ calculated for C25H20F4N6O2 513.16; found 513.19. HRMS (ESI): 
[M+H]+ calculated for C25H20F4N6O2 513.1583, found 513.1659. 
 
(2E)‐N‐{4‐[4‐Amino‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐3‐yl]phenyl}‐4‐[4‐chloro‐3‐
(trifluoromethyl)phenyl]‐4‐oxobut‐2‐enamide (ASDO3) was made according to the general procedure 
reported for ASDO1. 1H NMR (500 MHz, Chloroform-d) δ 10.40 (s, 1H), 9.66 (s, 1H), 8.28 (s, 1H), 8.21 
(s, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.93 (s, 1H), 7.90 – 7.87 (m, 3H), 7.62 (d, J = 8.4 Hz, 1H), 7.55 – 7.52 
(m, 2H), 7.34 (d, J = 14.9 Hz, 1H), 6.86 (s, 2H), 5.10 (hept, J = 6.8 Hz, 1H), 1.52 (d, J = 6.7 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 188.2, 152.2, 150.8, 146.9, 143.9, 143.8, 137.3, 136.4, 135.5, 131.9, 130.6, 
130.1, 130.1, 129.5, 129.5, 126.8, 125.6, 125.6, 124.5, 97.6, 34.5, 21.8. LCMS-LCQ: 4 mins, 5-95% 
MeCN, Rt = 0.65 mins, > 99% purity; [M+H]+ calculated for C25H20ClF3N6O2 529.12; found 529.15. HRMS 
(ESI): [M+H]+ calculated for C25H20ClF3N6O2 529.1288, found 529.1359. 
 
(2E)‐N‐{4‐[4‐amino‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐3‐yl]naphthalen‐1‐yl}‐4‐oxo‐4‐[3‐
(trifluoromethyl)phenyl]but‐2‐enamide (ASDO4) was made according to the general procedure reported 
for ASDO1. 1H NMR (500 MHz, Chloroform-d) 1H NMR (500 MHz, Chloroform-d) δ 9.55 (s, 1H), 8.39 (s, 
1H), 8.34 (s, 2H), 8.27 (s, 1H), 8.18 (d, J = 14.7 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.91 (d, J = 7.9 Hz, 
1H), 7.72 (d, J = 7.6 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 14.7 Hz, 1H), 
5.49 (s, 2H), 5.28 (hept, J = 6.5 Hz, 1H), 1.67 (d, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 188.09, 
176.93, 164.36, 157.07, 154.49, 137.26, 136.07, 133.89, 133.13, 131.95, 131.91, 130.27, 129.98, 
129.74, 129.62, 128.36, 127.67, 127.61, 127.55, 127.32, 126.59, 125.68, 125.65, 125.62, 120.25, 
100.23, 49.31, 22.05.LCMS-LCQ: 4 mins, 5-95% MeCN, Rt = 0.61 mins, > 99% purity; [M+H]+ calculated 
for C29H23F3N6O2 545.18; found 545.25. HRMS (ESI): [M+H]
+ calculated for C29H23F3N6O2 545.1835, 
found 545.2167. 
 
(2E)‐N‐{4‐[4‐Amino‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐3‐yl]‐3‐methylphenyl}‐4‐[4‐fluoro‐3‐
(trifluoromethyl)phenyl]‐4‐oxobut‐2‐enamide (ASDO6) was made according to the general procedure 
reported for ASDO1. 1H NMR (500 MHz, Chloroform-d) δ 8.97 (s, 1H), 8.37 (s, 1H), 8.35 (d, 1H), 8.32 – 
8.26 (m, 1H), 8.24 (d, J = 8.2 Hz, 1H), 8.09 (d, J = 14.8 Hz, 1H), 7.62 – 7.57 (m, 2H), 7.38 (t, J = 9.1 Hz, 
1H), 7.29 (s, 1H), 5.75 (s, 2H), 5.19 (hept, J = 6.7 Hz, 1H), 2.43 (s, 3H), 1.61 (d, J = 6.8 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 186.6, 161.6, 157.2, 154.5, 153.3, 143.4, 136.3, 135.9, 134.8, 134.7, 133.2, 
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133.1, 130.8, 130.7, 129.7, 128.6, 128.5, 126.9, 123.2, 118.0, 117.8, 98.4, 77.3, 49.1, 22.0, 17.9. LCMS-
LCQ: 4 mins, 5-95% MeCN, Rt = 2.89 mins, > 95% purity; [M+H]+ calculated for C26H22F4N6O2 527.17; 
found 527.21. HRMS (ESI): [M+H]+ calculated for C26H22F4N6O2 527.1740, found 527.2500. 
 
 
(E)-4-Anilino-1-[m-(trifluoromethyl)phenyl]-2-butene-1,4-dione (DO1) was made by dissolving (E)-4-oxo-
4-[3-(trifluoromethyl)phenyl]but-2-enoic acid (80 mg, 0.33 mmol, 1.5 eq.) in DCM (2mL) and DMF 
(200uL) in an oven dried, Ar (g) cooled 20 mL scintillation vial with septum top. TEA (61 uL, 0.44 mmol, 
2 eq.) and HATU (133 mg, 0.35 mmol, 1.6 eq.) were then added and the mixture was allowed to stir at 
RT for 15 min. Next, the solution was chilled to 0 oC before the drop-wise addition of aniline (20 uL, 0.22 
mmol, 1 eq.).  After 10 min., the reaction was warmed to RT, stirred for an hour and then warmed to 40 
oC. After mixing for 1 h at 40 oC, the reaction was cooled and then quenched with 25 mL NAHCO3. This 
mixture was extracted 2X with DCM, dried with MgSO4 and concentrated in vacuo. Purification was 
achieved by silica chromatography using a hexanes/ethyl acetate system (ethyl acetate gradient 
increased over time from 0 – 100%). Concentration of the fractions yielded 12.9 mg (18%) of DO1.1H 
NMR (400 MHz, DMSO-d6) δ 10.63 (s, 1H), 8.38 (d, J = 7.9 Hz, 1H), 8.31 (s, 1H), 8.12 – 8.06 (m, 1H), 
7.95 (d, J = 15.2 Hz, 1H), 7.85 (t, J = 7.8 Hz, 1H), 7.73 (dd, J = 8.6, 1.0 Hz, 2H), 7.41 – 7.34 (m, 2H), 
7.26 (d, J = 15.2 Hz, 1H), 7.16 – 7.09 (m, 1H). 13C NMR (100 MHz, DMSO) δ 189.2, 162.1, 139.1, 137.8, 
137.7, 133.2, 133.0, 130.8, 130.5, 130.4, 130.3, 130.0, 129.4, 125.4, 125.4, 124.6, 119.9. 
 
 
2‐[1‐methoxy‐2‐(3-methyl-4‐nitrophenyl)ethylidene]propanedinitrile (1d) was made according to the 
general procedure reported for 1a. 1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, 1H), 7.26 (m, 2H), 3.73 
(s, 3H), 3.68 (s, 2H), 2.61 (s, 3H). 
 
3‐[(4‐amino‐3‐methylphenyl)methyl]‐1‐(propan‐2‐yl)‐1H‐pyrazolo[3,4‐d]pyrimidin‐4‐amine (2d-amine) 
was made according to the general procedure reported for 2a followed by reduction with Zn dust as 
reported in the first Zn-reduction step of the general procedure for the coupling of 3-benzoylacrylic acids 
NO2
i) (COCl)2, DMF (cat.), DCM
ii) Malonitrile, DIPEA, THF
iii) DMS
NO2
OMe
CN
CN
41%
O
OH
i) Isopropyl hydrazine, EtOH
ii) Formamide, 160 oC, O.N.
iii) Zn, THF/AcOH
42%
H2N
N
N
N
N
NH2
1d
2d-amine
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with 3-phenyl pyrazolopyrimidines. The amine was purified by silica chromatography using a DCM/ethyl 
acetate solvent system (ethyl acetate gradient increased over time from 0 – 50%). This coupling partner 
is hindered, and thus we needed to reduce the nitro substituted precursor and obtain a very pure sample 
of the amine to carry on through to the next coupling step. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (s, 
1H), 6.77 (s, 1H), 6.75 (d, J = 7.9 Hz, 1H), 6.52 (d, J = 8.1 Hz, 1H), 5.47 (s, 2H), 4.97 (hept, J = 6.7 Hz, 
1H), 4.06 (s, 2H), 3.55 (s, 2H), 2.00 (s, 3H), 1.46 (d, J = 6.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 157.0, 
153.8, 152.7, 144.2, 144.0, 132.0, 130.3, 126.7, 123.1, 115.4, 99.9, 48.4, 34.2, 21.8, 17.3. 
 
(2E)!N!(4!{[4!amino!1!(propan!2!yl)!1H!pyrazolo[3,4!d]pyrimidin!3!yl]methyl}!2!methylphenyl)!4!oxo!4!
[3!(trifluoromethyl)phenyl]but!2!enamide (ASDO5) was made according to the general procedure 
reported for ASDO1 starting from the amine. 1H NMR (500 MHz, Chloroform-d) δ 9.33 (s, 1H), 8.32 (s, 
1H), 8.25 (d, J = 8.0 Hz, 1H), 8.19 (s, 1H), 8.12 – 8.06 (m, 2H), 7.90 (d, J = 7.8 Hz, 1H), 7.75 (s, 1H), 
7.69 (t, J = 7.9 Hz, 1H), 7.32 (d, J = 14.9 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 5.58 (s, 2H), 5.16 (hept, J = 
6.8 Hz, 1H), 4.33 (s, 2H), 2.34 (s, 3H), 1.63 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 188.2, 
176.4, 173.3, 167.0, 165.8, 152.3, 150.0, 146.9, 143.9, 137.3, 136.5, 135.5, 131.9, 130.7, 130.1, 129.5, 
126.8, 125.6, 124.5, 97.6, 50.2, 34.5, 21.8, 18.2. LCMS-LCQ: 7 mins, 5-95% MeCN, Rt = 3.09 mins, > 
99% purity; [M+H]+ calculated for C27H25F3N6O2 523.1990; found 523.21. HRMS (ESI): [M+H]
+ calculated 
for C27H25F3N6O2 523.1990, found 523.4167. 
 
 
1H and 13C NMR Spectra and LCMS Analysis 
 
ASDO1 1H NMR (400 MHz, DMSO-d6) 
 
HO
O
O
CF3
H2N
N N
N
N
HN O
O
CF3
i) (COCl)2, DMF (cat.), DCM
ii) Pyridine, 40 oC
ASDO5 (39%)
H2N
N
N
N
N
NH2
2d-amine
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ASDO1 13C NMR (126 MHz, CDCl3): It should be noted that we did not detect C-F heteronuclear coupling 
due to CF3 in the 
13C NMR mainly due to overlapping peaks. 
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ASDO1 LCMS
 
 
 
 
 
 
ASDO2 1H NMR (500 MHz, 1:1 Chloroform-d:DMSO-d6) 
 
	 																
S	18	
 
 
 
 
 
 
 
ASDO2 13C NMR (126 MHz, 1:1 CDCl3:DMSO-d6): It should be noted that we did not detect C-F 
heteronuclear coupling due to CF3 in the 
13C NMR mainly due to overlapping peaks. 
 
 
 
ASDO2 LCMS 
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ASDO6 1H NMR (500 MHz, Chloroform-d) 
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ASDO6 13C NMR (126 MHz, CDCl3): It should be noted that we did not detect C-F heteronuclear coupling 
due to CF3 in the 
13C NMR mainly due to overlapping peaks. 
 
 
 
 
	 																
S	21	
ASDO6 LCMS 
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